Lytix Biopharma Overview

  • Founded
  • 2003
Founded
  • Status
  • Public
  • Employees
  • 18
Employees
  • Stock Symbol
  • LYTIX
Stock Symbol
  • Share Price
  • $1.02
  • (As of Monday Closing)

Lytix Biopharma General Information

Description

Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its product, LTX-315, is an oncolytic peptide with the potential to personalize immunotherapy.

Contact Information

Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
OSL
Primary Office
  • Sandakerveien 138
  • 0484 Oslo
  • Norway
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Lytix Biopharma Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.02 $0.96 $0.91 - $2.57 $40.9M 40.1M 11.1K -$0.14

Lytix Biopharma Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 36,541 36,541
Revenue 2 2 1 35
EBITDA (3,734)
Net Income (5,572) (5,572) (4,448) (3,682)
Total Assets 23,008 23,008 3,821 1,977
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lytix Biopharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lytix Biopharma‘s full profile, request access.

Request a free trial

Lytix Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating
Drug Discovery
Oslo, Norway
18 As of 2022
00000
00.00 0000-00-00
00000000 00000

00 00000

boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000000000000
Durham, NC
000 As of 0000
00000
000000 - 000 00000

00000000

ua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000 000000000
Boston, MA
00 As of 0000
0000
00.00 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lytix Biopharma Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
G1 Therapeutics Formerly VC-backed Durham, NC 000 00000 000000 - 000 00000
00000000 Venture Capital-Backed Boston, MA 00 0000 00000000000 0000
000 000000000000 Venture Capital-Backed Barcelona, Spain 00 0000 00000000000 0000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 0000 000000000000 0000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
You’re viewing 5 of 12 competitors. Get the full list »

Lytix Biopharma Patents

Lytix Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3230318-B1 Immune checkpoint inhibitor combinations Active 11-Dec-2014 00000000000
JP-2016128399-A Immune checkpoint inhibitor combinations Granted 11-Dec-2014 00000000000 0
JP-6767096-B2 Combination of immune checkpoint inhibitors Active 11-Dec-2014 00000000000
ES-2819282-T3 Immune checkpoint inhibitor combinations Active 11-Dec-2014 00000000000
EP-3230318-A1 Immune checkpoint inhibitor combinations Granted 11-Dec-2014 A61K38/1729
To view Lytix Biopharma’s complete patent history, request access »

Lytix Biopharma Executive Team (16)

Name Title Board Seat Contact Info
Øystein Rekdal Ph.D Co-Founder, Chief Executive Officer & Managing Director
Gjest Breistein Chief Financial Officer
Gry Stensrud Ph.D Chief Technical Officer
Baldur Sveinbjørnsson Ph.D Chief Scientific Officer
John Svendsen Ph.D Co-Founder & Director of Discovery Research
You’re viewing 5 of 16 executive team members. Get the full list »

Lytix Biopharma Board Members (15)

Name Representing Role Since
Brynjar Forbergskog Self Board Member 000 0000
Evelina Vågesjö Ph.D Self Board Member 000 0000
Gert Munthe Self Chairman 000 0000
Jayson Rieger Ph.D Self Board Member 000 0000
Kjetil Hestdal Ph.D Self Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Lytix Biopharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lytix Biopharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lytix Biopharma‘s full profile, request access.

Request a free trial